436P Phase (Ph) II study of taminadenant (NIR178) + spartalizumab (PDR001) in patients (pts) with microsatellite stable (MSS) colorectal cancer (CRC)O. Saavedra Santa Gadea,R. Greil,M.J.A. de Jonge,D. Tan, G. Jerusalem,S. Damian, P. Grell, Z. Wainberg,J. Wolf, M. Joerger,M.S. Carlino,S. Kasper,T.A. Yap, J. Otero, X. Yang, V. Nesbitt, J. Kim,L. Ho Lee,S. Choudhury, T.A. LealANNALS OF ONCOLOGY(2021)引用 1|浏览12暂无评分AI 理解论文溯源树样例生成溯源树,研究论文发展脉络Chat Paper正在生成论文摘要